{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:01:46Z","timestamp":1754481706739,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,24]]},"DOI":"10.1182\/blood.2022017564","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:19:47Z","timestamp":1669310387000},"page":"2183-2185","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Axi-cel in LBCL: fulfill two\u00a0needs with one deed"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"21","key":"2022112416353946100_bib1","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2022112416353946100_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in\u00a0relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2022112416353946100_bib3","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2022112416353946100_bib4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2022112416353946100_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"volume-title":"Yescarta\u00ae (axicabtagene ciloleucel) [prescribing information]","year":"2022","key":"2022112416353946100_bib6"},{"issue":"10343","key":"2022112416353946100_bib7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"suppl 16","key":"2022112416353946100_bib8","article-title":"Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R\/R large B-cell\u00a0lymphoma (LBCL) in patients (pt) not\u00a0intended for hematopoietic stem cell\u00a0transplantation (HSCT): primary analysis\u00a0from the phase 2 PILOT study","volume":"40","author":"Sehgal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"volume-title":"Breyanzi\u00ae (lisocabtagene maraleucel) [prescribing information]","year":"2022","key":"2022112416353946100_bib9"},{"issue":"suppl 1","key":"2022112416353946100_bib10","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1182\/blood-2021-151611","article-title":"Improved quality of life (QOL) with lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, compared with standard of care (SOC) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R)\u00a0large B-cell lymphoma (LBCL): results from the phase 3 Transform study","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/21\/2183\/2018689\/blood-1013-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/21\/2183\/2018689\/blood-1013-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:19:55Z","timestamp":1669310395000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/21\/2183\/493309\/Axi-cel-in-LBCL-fulfill-two-needs-with-one-deed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":10,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017564","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}